Lyka Labs rallied 4.65% to Rs 156.50 after the company received the Central Drug Standard Control Organisation (CDSCO) approval for manufacturing and marketing Pregabalin Gel for the use in patients with Diabetic Neuropathic Pain.
The most effective way to treat Diabetic Neuropathic Pain is a comprehensive approach and patients are often prescribed specific oral pain killers such as Pregabalin Capsules, which have been available in the Indian Market for over 2 decades.Pregabalin Capsules are known to cause side effects. One approach to overcome side effects of oral drugs used for pain relief is to use their topical applications such as gel, ointments, or creams. The company has developed a novel patent pending topical gel formulation of Pregabalin.
Lyka Labs in the development, manufacture and marketing of quality finished dosages.
The company reported consolidated net profit of Rs 1.44 crore in Q2 FY25 as compared with net loss of Rs 1.85 crore posted in corresponding quarter last year. Net sales increased 31.6% YoY to Rs 30.11 crore in Q2 FY25.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
